Please use this identifier to cite or link to this item: http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/25921
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNovychenko, Yuliia-
dc.contributor.authorKhukhlina, Oksana-
dc.contributor.authorKovalenko, Svitlana-
dc.contributor.authorDudka, Inna-
dc.date.accessioned2024-11-13T11:53:17Z-
dc.date.available2024-11-13T11:53:17Z-
dc.date.issued2021-
dc.identifier.urihttp://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/25921-
dc.description.abstractAbstract. The article describes the experience of practical use of Ukrainian drug Lipin (phosphatidylcholine (lecithin)) for the treatment of patients with pneumonias associated with COVID-19. The drug does not have any analogues at the market of phosphatidylcholines, possesses a strong anti-hypoxic action, promotes oxygen diffusion rate from the lungs into the blood and from the blood to the tissues, normalizes the processes of tissue respiration, restores functional activity of the endothelial cells, and improves microcirculation and rheological blood properties.uk_UA
dc.language.isoenuk_UA
dc.publisherPharmacologyOnLine (міжнародний онлайн-журнал)uk_UA
dc.subjectpneumoniauk_UA
dc.subjectCOVID-19uk_UA
dc.subjecttreatmentuk_UA
dc.subjectphosphatidylcholineuk_UA
dc.titleEffect of Lipin administration in a comprehensive treatment of community-acquired pneumonia associated with COVID-19uk_UA
dc.typeArticleuk_UA
Appears in Collections:Статті

Files in This Item:
File Description SizeFormat 
Novychenko et al. Effect.pdf158.76 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.